Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Espoo – page 8

385 clinical trials in Espoo, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Espoo at a glance
385
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

385 trials in Espoo

Open in trial search

Acute myeloid leukaemia

Recruiting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Follicular lymphoma

Recruiting

Study on Rituximab, Lenalidomide, and Tafasitamab for Treating High-Risk and Low-Risk Follicular Lymphoma Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Karolinska University Hospital

Intensive care

Recruiting

Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Dalteparin Sodium
  • Sponsor:Region Hovedstaden

Colorectal cancer metastatic+1

Recruiting

Study on the Effects of Fluorouracil and Capecitabine in Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:HUS-yhtymae

Acute lymphocytic leukaemia

Recruiting

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients 55+ with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Cardiff University

Extra-osseous Ewing's sarcoma+5

Recruiting

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Generalised anxiety disorder

Recruiting

Study on ITI-1284 for Patients with Generalized Anxiety Disorder Not Responding to Current Treatment

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:ITI-1284
  • Sponsor:Intra-Cellular Therapies Inc.

Pancreatic carcinoma+1

Recruiting

Study on Preventing Blood Clots in Pancreatic Cancer Patients Using Tinzaparin Sodium and Enoxaparin Sodium During Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:HUS-yhtymae

Intracranial aneurysm

Recruiting

Study on Managing Risk Factors in Patients with Unruptured Brain Aneurysms Using Carbasalate Calcium and Intensive Blood Pressure Treatment

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Heidelberg University

Juvenile idiopathic arthritis

Recruiting

Study of Sarilumab for Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA)

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Sarilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hormone-refractory prostate cancer+1

Recruiting

Study of Opevesostat, Olaparib, and Cabazitaxel in Patients with Advanced Prostate Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Espoo

What the registry says about research in the country

01 Infectious Disease Prevention

Comprehensive research focusing on vaccine development for multiple respiratory viruses, including studies of new formulations against influenza, RSV, and pneumococcal infections. Clinical trials are evaluating innovative immunization approaches for various age groups.

  • Influenza Vaccines
  • RSV Prevention
  • Pneumococcal Protection

Particular emphasis on protecting vulnerable populations such as infants, toddlers, and adults over 60 years old.

02 Cardiovascular Health

Advanced research in cardiovascular medicine, focusing on preventing stroke in atrial fibrillation patients and developing new treatments for acute myocardial infarction. Studies include innovative drug therapies and preventive measures.

  • Stroke Prevention
  • Heart Attack Management
  • Blood Clot Prevention

Trials are investigating new anticoagulants and emergency interventions for heart conditions.

03 Surgical and Specialized Care

Innovative research in surgical procedures and specialized medical conditions, including studies on frostbite treatment, plastic surgery outcomes, and post-operative care protocols.

  • Surgical Complications
  • Emergency Medicine
  • Post-Operative Care

Focus on improving surgical outcomes and developing better treatment protocols for specialized conditions.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.